Cancer and the microbiota
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
A host’s microbiota may increase, diminish, or have no effect at all on cancer susceptibility. Assigning causal roles in cancer to specific microbes and microbiotas, unraveling host-microbiota interactions with environmental factors in carcinogenesis, and exploiting such knowledge for cancer diagnosis and treatment are areas of intensive interest. This Review considers how microbes and the microbiota may amplify or mitigate carcinogenesis, responsiveness to cancer therapeutics, and cancer-associated complications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss of microbial diversity (dysbiosis) is associated with chronic health conditions (26–28) and cancer (8–10), and is also associated with poor outcomes to certain forms of cancer therapy including allogeneic stem cell transplant (29).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [8]
In the citing paper
“It has recently emerged that factors beyond tumor genomics influence cancer development and therapeutic responses (4–7), including host factors such as the gastrointestinal (gut) microbiome (8–10).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [8]
In the citing paper
“their gene count that exceeds the human genome’s gene count by ~100-fold and enables diverse metabolic programming”
From The microbiome and human cancer (2021) · cites this paper as [31]
In the citing paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
From The microbiome and human cancer (2021) · cites this paper as [31]
In the citing paper
“their effects on host immune system development and activity, including antitumor immunosurveillance (27–31).”
From The microbiome and human cancer (2021) · cites this paper as [31]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Self-citationMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Inflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754
Research works printed but not linked: 1
- 10.1111/j.1572-0241.2000.01860.x · doi:10.1111/j.1572-0241.2000.01860.x · Paper page
Cited by
Items 901–1,000 of 1,001
Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Rana, D., Salave, S., Perla, A., Nadkarni, A., Kolhe, S., Jindal, A. B., Mandoli, A., Dwivedi, P., & Benival, D. M. (2022) · Current Drug Targets · doi:10.2174/1389450123666220309101345 · Cited by 6
Nandi, S. K., Basu, S., Bhattacharjya, A., Ghosh, R. D., Bose, C. K., Mukhopadhyay, S., & Bhattacharya, R. K. (2022) · Nutrition · doi:10.1016/j.nut.2022.111787 · Cited by 6
Human microbiota colonization and pancreatic ductal carcinoma
Yuan, F., Yang, G., Yang, J., Ren, J., You, L., & Zhao, Y. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2080526 · Cited by 6
“For many malignant tumours, when carcinoma is detected, the window of opportunity to identify the causative bacteria may have passed, increasing the difficulty of determining the causal relationship between microbial changes and the occurrence of carcinoma (Garrett 2015).”
BackgroundZhao, Y., Bao, D., Sun, Y., Meng, Y., Li, Z., Liu, R., Lang, J., Liu, L., & Gao, L. (2023) · PeerJ · doi:10.7717/peerj.15462 · Cited by 6
“Dysregulation of the gut microbiome is associated with several diseases in humans and animals (Dworkin et al., 2006; Bäckhed et al., 2012; Hsiao et al., 2013; Garrett, 2015).”
BackgroundXu, H., Guo, N. N., Zhu, C. Y., Ye, L. Y., Yan, X. Y., Liu, Y. Q., Zhang, Z. Y., Zhang, G., & Hussain, L. (2024) · ACS Omega · doi:10.1021/acsomega.3c09667 · Cited by 9
“24,25 26 − 28 Inflammation of the lung and intestine can trigger changes in the gut micro-environment, thereby initiating the development of cancer.”
BackgroundMicrobiome in gynecologic malignancies: a bibliometric analysis from 2012 to 2022
Lin, X., Zheng, W., Zhao, X., Zeng, M., Li, S., Peng, S., Song, T., & Sun, Y. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1769 · Cited by 6
“Extensive dysbiosis of the gut microbiota has been shown to induce changes in inflammation, metabolic disorders, and immune dysregulation, thereby altering disease progression and treatment outcomes (61,62).”
Obesity and Cancer—Opportunities to Break the Link
Argolo, D. F. S. D. T. E., Hudis, C. A., & Iyengar, N. M. (2016) · Current Breast Cancer Reports · doi:10.1007/s12609-016-0200-0 · Cited by 8
Lang, T., Zou, S., Huang, K., Guo, M., Liu, X., & He, X. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.10.018 · Cited by 7
Future Perspectives: Microbiome, Cancer and Therapeutic Promise
Banerjee, S., & Robertson, E. S. (2019) · Current cancer research · doi:10.1007/978-3-030-04155-7_17 · Cited by 7
Effect of Helicobacter pylori treatment on the long-term mortality in patients with type 2 diabetes
Kim, Y., Kim, Y. A., Kim, H. J., Kim, S., Hwangbo, Y., Kim, J. G., Kim, J. J., & Choi, I. J. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.428 · Cited by 6
“Dysbiosis might have negative effects on the process of carcinogenesis including initiation, progression, and dissemination of cancer or cancer treatment efficacy [33,34].”
BackgroundKhuda‐Bukhsh, A. R., Saha, S. K., Das, S., & Saha, S. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819547-5.00018-3 · Cited by 6
Hajeebu, S., Ngembus, N. J., Bandi, P. S., Panigrahy, P. K., & Heindl, S. E. (2021) · Cureus · doi:10.7759/cureus.17415 · Cited by 7
“The third step is to extract the key features from the gene sequences in the microbes and oncogenes and determine if the oncogenes mutated from the microbes [1,5].”
BackgroundCampillo-Gimenez, L., Ríos-Covián, D., Rivera–Nieves, J., Kiyono, H., Chu, H., & Ernst, P. B. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.752304 · Cited by 6
“Other bacterial species, such as Fusobacterium nucleatum, have been implicated in CRC without obvious inflammation (Castellarin et al., 2012; Sears and Garrett, 2014; Garrett, 2015; Wang and Jia, 2016; Dejea et al., 2018; Yang and Jobin, 2018).”
BackgroundShimizu, M., Miyanaga, A., Seike, M., Matsuda, K., Matsumoto, M., Noro, R., Fujita, K., Mano, Y., Furuya, N., Kubota, K., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14463 · Cited by 4
“pylori), Fusobacterium nucleatum, human papilloma virus, and Escherichia coli can lead to various types of cancer.(8) Particularly, H.”
BackgroundMG7: Configurable and scalable 16S metagenomics data analysisPreprint
Alekhin, A., Kovach, E., Manrique, M., Pareja-Tobes, P., Pareja, E., Tobes, R., & Pareja-Tobes, E. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/027714 · Cited by 6
The Diagnostic Potential & Interactive Dynamics of the Colorectal Cancer ViromePreprint
Hannigan, G. D., Duhaime, M. B., Ruffin, M. T., Koumpouras, C. C., & Schloss, P. D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/152868 · Cited by 7
Gut microbiota affects prostate cancer risk through steroid hormone biosynthesisPreprint
Kalinen, S., Kallonen, T., Gunell, M., Ettala, O. O., Jambor, I., Knaapila, J., Syvänen, K. T., Taimen, P., POUTANEN, M. H., Ohlsson, C., et al. (2021) · medRxiv · doi:10.1101/2021.08.19.21262274 · Cited by 6
“a collection of all microbes in the gastrointestinal tract, is acknowledged to affect many metabolic pathways and pathogenetic processes in the human body.(8) Further, the state of gut dysbiosis i.”
BackgroundZhao, M., Tian, J., Hou, W., Yin, L., & Li, W. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1416385 · Cited by 6
“While essential for maintaining physiological homeostasis, their imbalance has been implicated in a spectrum of pathologies, including oncogenesis (Garrett, 2015; Zitvogel et al., 2018).”
BackgroundA comprehensive insight of complex interplay of microbiota in pulmonary diseases
Yu, J., Li, P., Yu, Y., Ma, Y., Zuo, S., Chen, H., Guo, F., & Sun, Y. (2024) · Discover Medicine · doi:10.1007/s44337-024-00063-1 · Cited by 8
Zouiouich, S., Wan, Y., Vogtmann, E., Porras, C., Abnet, C. C., Shi, J., & Sinha, R. R. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-0839 · Cited by 5
Bacterial dormancy: strategies and molecular mechanisms for a sleeping beauty system
Abid, S. A., Al-Kadmy, I. M. S., Aziz, S. N., Garallah, E. T., Aziz, R. N., Ramadan, Y. N., & Hetta, H. F. (2025) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000422 · Cited by 9
Yang, Y., Meng, Y., Xu, Z., Zhang, Q., Li, M., Kong, F., Zhang, S., Li, X., & Zhu, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02038-9 · Cited by 9
Charalambous, H., Brown, C., Vogazianos, P., Katsaounou, K., Nikolaou, E., Stylianou, I., Papageorgiou, E., Vraxnos, D., Aristodimou, A., Chi, J., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70075 · Cited by 7
Zuo, Z., Zeng, S., Ou, X., Du, L., & Guo, Y. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07903-7 · Cited by 6
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future
Luo, H.-Y., Cao, L., Zhou, K., Xiao, Y., Li, Z., Liu, B., & Bu, L. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.08.001 · Cited by 6
Yang, J., Dong, Y., Chen, Y., Liang, H., Rong, S., Liu, Z., & Lang, Q. (2025) · Oncology Letters · doi:10.3892/ol.2025.15273 · Cited by 10
“The core carcinogenic mechanisms of intratumoral microorgan‑ isms include genetic instability, immune microenvironment remodeling and metabolic intervention (16,17).”
Špiljak, B., Ozretić, P., Brailo, V., Škrinjar, I., Brzak, B. L., Rogulj, A. A., Butić, I., Andrašević, A. T., & Juras, D. V. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04611-w · Cited by 5
“The EMT, and immune evasion (Radaic and Kapila 2021 ; Cugini et al. 2021 ; Devaraja and Aggarwal 2025 ; Garrett 2015 ; Kostic et al. 2013 ; Rubinstein et al. 2013 ; Pignatelli et al. 2023; Wang et al. 2024 ; Chen et al. 2023a , b; Sharaf and Hijazi 2022 ; Olsen and Yilmaz 2019; Jia et al. 2019 ;…”
Pathogenic mechanisms and therapeutic potential of the microbiome in premature ovarian insufficiency
Ma, S., Zheng, L., Zhuang, X., Wang, M., & Zou, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1734367 · Cited by 5
“The human microbiome far exceeds a simple collection of bacteria; it essentially functions as an ‘ organ ’ – a dynamic, functionally active system with systemic endocrine and immune regulatory capabilities (28).”
Wang, J., Su, Z., Zhang, X., Wang, S., Chen, X., Xu, X., He, B., & Zheng, Y. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123915 · Cited by 6
Morel, C., Li, R., Fiuza‐Luces, C., Brougham, M. F. H., Pascual-Gázquez, J. F., Torquati, L., & Iniesta, R. R. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.101300 · Cited by 5
“A diverse microbiota is associated with better immunotherapy responses [99 – 102], by maintaining gut barrier integrity and preventing systemic inflammation [11,29,30].”
Zhai, Z., Li, X., Shang, S., Ma, S., Liang, X., Yin, S., Wu, M., Yu, J., Song, Q., & Chen, D. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-025-02623-z · Cited by 5
“For instance, Fusarium species bind to TLR4 on CRC cells, activating NF-κB signaling, which increases inflammatory cytokines and downstream ERK signaling, leading to an increase in 12,13-EpOME, collectively enhancing anti-tumor immunity [95].”
Yao, Q., Chen, S., Qian, W., Yang, C., & Li, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1724908 · Cited by 7
“Notably, the gut microbiota — as a core microecosystem maintaining intestinal mucosal barriers, immune homeostasis, and metabolic equilibrium — has gained increasing prominence in CRC research (6 – 8).”
Biomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy
Wu, Q., Chon, J. S. D., Feng, Y., Liang, K., Li, S., Zhang, C. Y., & Ge, J. (2026) · Advanced Science · doi:10.1002/advs.202521580 · Cited by 11
“This finding was further substantiated by the discovery of Coley’s toxin, a bacterial extract capable of treating sarcomas, which demonstrated the capacity of specific microbes to combat cancer by activating anti-tumor immune responses [ 162–164 ].”
Defining the tumor microenvironment of non‐small cell lung cancer
Embaye, K. S., Blick, T., Naei, V. Y., O'Byrne, K. J., Hughes, B. G. M., & Kulasinghe, A. (2026) · Immunology and Cell Biology · doi:10.1111/imcb.70114 · Cited by 5
“147 Beyond systemic effects, local microbiomes at tumor sites can directly shape the tumor niche.”
Mycobiome and Mycobiome-Associated Diseases
Hagihara, M., Kato, H., Shibata, Y., Umemura, T., Ariyoshi, T., Hirai, J., Asai, N., Mori, N., & Mikamo, H. (2023) · Medical Mycology Journal · doi:10.3314/mmj.23-002 · Cited by 5
Roles of long non‑coding RNA SNHG16 in human digestive system cancer (Review)
Zhao, L., Kan, Y., Wang, L., Pan, J., Li, Y., Zhu, H., Yang, Z., Xiao, L., Fu, X., Peng, F., et al. (2024) · Oncology Reports · doi:10.3892/or.2024.8765 · Cited by 7
“Evidence has suggested that bacterial infection serves a key role in tumor progression, such as in EC (55).”
BackgroundAltered microbial diversity and composition of multiple mucosal organs in cervical cancer patients
Peng, L., Ai, C., Dou, Z., Li, K., Jiang, M., Wu, X., Zhao, C., Li, Z., & Zhang, L. (2024) · BMC Cancer · doi:10.1186/s12885-024-12915-1 · Cited by 7
“First, tum-origenesis and a variety of other factors cause damage to the mucosal barrier, which may provide a pathway for opportunistic organisms to colonize the tumor, creating an intra-tumoral microbiota [7].”
BackgroundAtovaquone-proguanil and reduced digestive cancer risk: a Toxoplasma gondii connection
Israel, A., Israel, S., Weizman, A., Ashkenazi, S., Vinker, S., Magen, E., & Merzon, E. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2545412 · Cited by 3
Insights Into the Relationship Between Gut Microbiota and Colorectal Cancer
Mota, J. F., Walter, J., & Prado, C. M. M. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0419-4 · Cited by 7
Bao, C., Wang, K., Ding, Y., & Kong, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01298 · Cited by 5
“Previous studies have suggested that some microbes promote cancer development by regulating host cell signaling cascades or inducing histologic changes (59, 60).”
BackgroundMicrobes in human oral cavity: a review
Sarmah, R., Khan, R. A., & Devi, K. R. (2020) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000227 · Cited by 5
Wen, X., Ye, X., Yang, X., RuJin, J., Qian, C., & Wang, X. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02995-5 · Cited by 5
Hidifira, A. M., Alvares-Saraiva, A. M., Pérez, E. C., Spadacci-Morena, D. D., de Araújo, R. S., & Lallo, M. A. (2023) · Experimental Parasitology · doi:10.1016/j.exppara.2023.108606 · Cited by 5
Association between gut microbiota and gastric cancers: a two-sample Mendelian randomization study
Chang, Y., Gao, G., & Feng, C. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1383530 · Cited by 5
“A balanced microbiota plays a protective role against cancer development, whereas dysbiosis may promote oncogenesis (Garrett, 2015; Meng et al., 2018).”
BackgroundShijimaya, T., Tahara, T., Yamazaki, J., Kobayashi, S., Matsumoto, Y., Nakamura, N., Takahashi, Y., Tomiyama, T., Fukui, T., Shibata, T., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67410-1 · Cited by 5
Guo, M., Sun, Y., Wang, X., Wang, Z., Yuan, X., Chen, X., Yuan, X., & Wang, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910486 · Cited by 6
“In addition to the existing microbiota near the tumor tissue, mucosal impairment caused by tumor growth and some components of the TME can also bring external microorganisms into the tumor tissue [100,101].”
BackgroundDhilipkannah, P., Sachdeva, A., Holden, V. K., & Jiang, F. (2024) · Current Oncology · doi:10.3390/curroncol31100444 · Cited by 6
“It has been recently suggested that the microbiome plays crucial roles in tumor formation via direct mutagenesis, promoting the survival of tumor-initiating cells, or inducing pro-tumorigenic immune responses [4–13].”
BackgroundShijimaya, T., Tahara, T., Shimogama, T., Yamazaki, J., Kobayashi, S., Nakamura, N., Takahashi, Y., Tomiyama, T., Fukui, T., & Naganuma, M. (2024) · Epigenomics · doi:10.1080/17501911.2024.2418803 · Cited by 6
Guan, X., Bu, F., Fu, Y., Zhang, H., Xiang, H., Chen, X., Chen, T., Wu, X.-J., Wu, K., Liu, L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111338 · Cited by 8
Sonnenberg, A., Turner, K., & Genta, R. M. (2017) · Colorectal Disease · doi:10.1111/codi.13716 · Cited by 5
Xiong, Y., Song, W., Shen, L., Wang, Y., Zhang, J., Hu, M., Liu, Y., Li, J., Musetti, S., Liu, R., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000168 · Cited by 5
Personalized nutrition for colorectal cancer
Wang, K., & Song, M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.02.004 · Cited by 7
Microbiome dysbiosis inhibits carcinogen-induced murine oral tumorigenesis
Chen, Y., Huang, K., Wu, J., Liu, T., Chen, J.-W., Xie, J., Chen, M.-Y., Wu, L., & Tung, C. (2022) · Journal of Cancer · doi:10.7150/jca.75947 · Cited by 5
Liu, Y., Jiang, Z., Yang, H., Yuan, J., Zeng, J., Wu, J., & Xu, Z. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2708250 · Cited by 7
Wojciechowski, S., Majchrzak-Gorecka, M., Biernat, P., Odrzywołek, K., Pruss, Ł., Zych, K., Majta, J., & Milanowska, K. (2022) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2022.151560 · Cited by 6
Editing of a Specific Strain of Escherichia coli in the Mouse Gut Using Native Phages
Li, P., Li, Z., Pei, J., Jingchao, C., Li, Y., Guosheng, L., & Wang, H. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01804-22 · Cited by 4
Association of Microbes with Breast Cancer
Noguti, J., & Lee, D. J. (2019) · Current cancer research · doi:10.1007/978-3-030-04155-7_7 · Cited by 5
Integrating the microbiome into the barrier theory of cancer
Ewald, H. A. S., & Ewald, P. W. (2020) · Evolutionary Applications · doi:10.1111/eva.13066 · Cited by 7
“The responders also had a higher incidence of immune-related colitis, which is a common side effect of checkpoint inhibition therapy (Garrett, 2015) and probably reflects a tradeoff associated with immune checkpoints, namely that relaxation of the constraints on immunological attacks increases the risk of friendly fir…”
BackgroundInfluentialRuggiero, M., & Aterini, S. (2015) · Springer eBooks · doi:10.1007/978-3-642-27841-9_1843-4 · Cited by 5
mbDriver: identifying driver microbes in microbial communities based on time-series microbiome data
Tan, X., Xue, F., Zhang, C., & Wang, T. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae580 · Cited by 4
A Novel Prognostic Signature of Mitophagy-Related E3 Ubiquitin Ligases in Breast Cancer
Bian, K., Yang, C., Zhang, F., & Huang, L. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041551 · Cited by 5
Charting the landscape of intratumoral microbiota in lung cancer: From bench to bedside
Yu, Y., Wu, K., Song, H., & Wang, K. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189348 · Cited by 4
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects
Liu, Y., Miao, K., & Yang, X. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.01.001 · Cited by 4
Hahn, J., Harimoto, T., Chen, Y.-Y., Liguori, F., Leong, K. W., & Danino, T. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00598 · Cited by 5
Crosstalk Between Intratumoral Microbes and Tumor Immunity: Implications for Tumor Therapy
Li, F., Qiao, L., Liang, X., Zhang, Y., Liang, N., Xie, J., Deng, G., Hao, Y., Hu, P., Wu, X., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71575 · Cited by 6
“The origins of immunotherapy stem from an understanding of the coadaptation between the host and microbes, utilizing bacteria to trigger the immune system to attack and destroy cancer [133].”
Cao, Q., Yang, Y., Bai, S., & Shen, J. (2026) · BMC Oral Health · doi:10.1186/s12903-026-07813-w · Cited by 5
“Finally, specific oral pathogens, including Porphyromonas gingivalis and Fusobacterium nucleatum , actively suppress host immune surveillance [54, 55].”
The landscape of tissue-resident microbiota across normal, polyp, and colorectal cancer tissues
Xiang, H., Shen, B., Lao, W., Bai, B., Chen, M., Zhou, L., Yu, G., Zhang, W., Chen, H., Wang, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69705-5 · Cited by 6
Chen, H., Lou, G., Meng, F., Zhang, Y., Kuang, H., & Yang, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1734792 · Cited by 5
“These metabolites can directly induce DNA damage in host cells, thus playing a key initiating role in tumor development (59, 60, 88).”
Circadian rhythms and microbiota: molecular crosstalk and its implications for health and disease
Wu, G., Zhang, J., Yan, S., Liu, N., Chen, W., Wu, F., Wang, Z., Zhang, J., Yang, Y., Deng, Y., et al. (2026) · Biology Direct · doi:10.1186/s13062-026-00748-w · Cited by 4
“In cancer biology, the microbiota interacts with host genetics and environmental factors to regulate carcinogenesis, therapeutic efficacy, and disease progression through metabolic and immune modulation [19].”
Cancer and aging: complex associations and therapeutic targets
Liang, J., Zang, S., Zhe, W. A. N. G., & Zhang, R. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00423-6 · Cited by 6
“The existence of intratumoral microbiota (microorganisms residing within tumor tissues) has now been firmly established [91, 92].”
Chen, D., Hu, S., Wang, X., Chen, Z., & Xu, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1463309 · Cited by 4
Pădure, A., Talpos-Niculescu, I. C., Ciordas, P. D., Romanescu, M., Chiş, A. R., Rusu, L. C., & Sîrbu, I. O. (2025) · Microorganisms · doi:10.3390/microorganisms13071565 · Cited by 5
“Emerging evidence indicates that dysbiosis might contribute to carcinogenesis [25,26] through several mechanisms, including chronic inflammation, the production of genotoxins that can damage host DNA, and the disruption of host immune responses [26,27].”
Abolhassani, A., Esmaili, H., Rahati, S., & Jafarnejad, S. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10741-w · Cited by 9
“As confirmed in CRC, controlling the immune system has a direct impact on the gut microflora, which in turn affects the tumor microenvironment and consequently the development of CRC [90, 91].”
Restaino, S., Pellecchia, G., Arcieri, M., Pericolini, E., Bogani, G., Poli, A., Paparcura, F., Pregnolato, S., Armenise, D., Frossi, B., et al. (2025) · Cells · doi:10.3390/cells14201590 · Cited by 4
Liver Flukes and the Microbiota in Cancer
Osborne, L. C., & Wegener-Parfrey, L. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.05.038 · Cited by 4
Microbiota/microbiome urine and bladder cancer
Коган, М. И., Naboka, Y. L., Ryzhkin, A. V., & Vasilyev, O. N. (2020) · Cancer Urology · doi:10.17650/1726-9776-2020-16-2-97-103 · Cited by 7
Manzanares‐Leal, G. L., Coronel-Martínez, J. A., Rodríguez-Morales, M., Bustamante-Montes, L. P., Sandoval-Trujillo, H., & Ramírez‐Durán, N. (2021) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_757_19 · Cited by 4
The Impact of the Intestinal Microbiota in Therapeutic Responses Against Cancer
Bonvalet, M., Daillère, R., Roberti, M. P., Rauber, C., & Zitvogel, L. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_27 · Cited by 5
Pharmacological Mechanism of Pingxiao Formula against Colorectal Cancer
Yu, W., Lu, C., Wang, G., Liang, Z., Jiang, Z., Liu, Y., & Yan, J. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/7884740 · Cited by 5
“Collectively, the PX formula is able to reverse the tumor-promoting phenotype of TAMs and thus reshape the communication between TAMs and other cell populations or microbes, which has also been considered a causal factor for neoplastic processes and infuences the responsiveness to cancer therapeutics [31].”
BackgroundMyD88 Signaling Accompanied by Microbiota Changes Supports Urinary Bladder Carcinogenesis
Knezović, D., Roje, B. M., Vilović, K., Franković, L., Korać-Prlić, J., & Terzić, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137176 · Cited by 4
“Analyzing the contribution of molecules that are transducing signals of microbial presence to the cell interior [12] can give us fundamental insight into the importance of bacteria in cancer development [13,14].”
BackgroundThe Microbiota in Cancer: A Secondary Player or a Protagonist?
García, A. M. G., Lopez-Munoz, F. J., & García‐Rico, E. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080463 · Cited by 6
“This imbalance systemic in anti-inflammatory bacteria such as Faecalibacterium prausnitzii can promote a chronic inflammatory environment in the gut, which is a known risk factor for the development of colorectal cancer [56].”
BackgroundLi, M., Qu, R., Li, P., Mo, X., Liu, J., Dong, B., Liu, L., & Xu, Z. Z. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134203 · Cited by 5
Palkovský, M., Modráčková, N., Bunešová, V., Liberko, M., & Soumarová, R. (2024) · In Vivo · doi:10.21873/invivo.13803 · Cited by 8
Yang, C., Qin, L.-H., Li, L., Wei, Q.-Y., Long, L., & Liao, J.-Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-13656-5 · Cited by 8
“Studies suggest that the interaction between the gut microbiota and the immune system may influence the effectiveness of cancer treatments [34].”
Oral Microbiome Dysbiosis and Citrullination in Rheumatoid Arthritis
Xia, Y., Mankia, K. S., Do, T., & Meade, J. L. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-79146-8_12 · Cited by 7
Cui, X., Yi, C., Liu, J., Qi, J., Deng, W., Yuan, X., Zhou, R., Chen, M., Xiang, Q., & Xu, H. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.9.6 · Cited by 7
Interacciones entre microbiota y huésped
Pascual, I. P., Martínez, A. R., & Moral, S. D. L. F. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.02.010 · Cited by 7
Biofilm formation and its regulation by extracellular appendages in Pseudomonas aeruginosa
Ramzan, A., Rehman, T., But, M. S., Imran, M., & Qaisar, U. (2022) · World Journal of Biology and Biotechnology · doi:10.33865/wjb.007.03.0516 · Cited by 4
Plitt, T., & Faith, J. J. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101735 · Cited by 3
Najjary, S., Kros, J. M., Stricker, B. H. C., Ruiter, R., Shuai, Y., Kraaij, R., Steen, K. V., van der Spek, P. J., van Eijck, C. H. J., Ikram, M. A., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.6860 · Cited by 4
Symbiotic symphony: Understanding host-microbiota dialogues in a spatial context
Chatterjee, S., Leach, S. T., Lui, K., & Mishra, A. (2024) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2024.03.001 · Cited by 4
Fang, Q., Xu, M., Yao, W., Wu, R., Han, R., Kawakita, S., Shen, A., Guan, S., Zhang, J., Sun, X., et al. (2024) · Discover Oncology · doi:10.1007/s12672-024-01257-w · Cited by 5
“By influencing metabolic pathways, suppressing immune cell function, and generating pro-inflammatory factors, the gut microbiota promotes the occurrence and advancement of lung cancer [6–9].”
BackgroundVomocytosis By Macrophages: A Crucial Event In The Local Niche of Tumors
Sharma, N. K., Sarode, S. C., Sarode, G. S., & Patil, S. (2019) · Future Oncology · doi:10.2217/fon-2019-0078 · Cited by 4
Bioactive Molecules of the Human Microbiome
Pauer, H., Glatthardt, T., Ferreira, N. V., Ferreira, R. B. R., & Antunes, L. C. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815249-2.00012-9 · Cited by 8
Probiotics in Lung Cancer: An Emerging Field of Multifarious Potential and Opportunities
Kurakula, M., & Rao, G. K. (2020) · Springer eBooks · doi:10.1007/978-981-15-8214-1_7 · Cited by 4
Microbes in Tumoral In Situ Tissues and in Tumorigenesis
Xue, F., Han, L., Ma, S., Zhao, L., Wang, L., Zhang, K., Yin, P., Guo, L., Wei, J., & Li, Q. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.572570 · Cited by 6
“…some possible relationships between tumors and microbes in different types of cancers (Nilsson et al., 2006; Guo et al., 2012; Kostic et al., 2012; Garrett, 2015; Mitsuhashi et al., 2015; Audirac-Chalifour et al., 2016; Lee Y. C. et al., 2016; Liu H. X. et al., 2018; Okushin et al., 2018; Aykut…”
BackgroundMinaya, D. M., Weinstein, N., & Czaja, K. (2021) · Nutrients · doi:10.3390/nu13124515 · Cited by 4
Microbiota: In Health and in Sickness, From Birth to Death
Kuk, S., Uyar, Y., Karaca, S., & Yazar, S. (2016) · Turkish Journal of Parasitology · doi:10.5152/tpd.2016.4789 · Cited by 6
GUT MICROBIOTA ALTERATIONS BY NUTRITIONAL SUPPLEMENT IMUREGEN
Kubelková, K., Rychlík, I., Crhánová, M., Karasová, D., Slížová, D., Žáková, J., Luksikova, L., & Macela, A. (2020) · Military Medical Science Letters · doi:10.31482/mmsl.2020.008 · Cited by 4
“The modulatory effect of a mammal’s gut microbiome has been documented in relation to the immune system’s maturation and its function (2), orchestration of microbiota–gut–brain communication (3-5), and influencing the origin and therapy of cancers (6,7).”
BackgroundLance, P. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_14 · Cited by 5
Metadata
- Authors
- Garrett, W. S.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Garrett, Wendy S.
- ORCID
- Garrett, Wendy S.
- Venue
- Science
- Published
- 2015-04-03
- Volume
- 348
- Issue
- 6230
- Pages
- 80-86
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5535753
- OpenAlex
- W2073924079
- Cited by
- 1,404
- References
- 119
- Citations by year
- 2026: 145 · 2025: 169 · 2024: 169 · 2023: 151 · 2022: 162 · 2021: 141 · 2020: 127 · 2019: 106 · 2018: 77 · 2017: 68 · 2016: 58 · 2015: 29
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (R01CA154426)
- Burroughs Wellcome Career in Medical Sciences Award
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, cancer susceptibility, carcinogenesis, host-microbe interactions, cancer therapy response, cancer diagnosis
- MeSH terms
- Humans, Immunotherapy, Neoplasms, Carcinogenesis, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.